Hershey Medical Center Research Trials: September 2024 (IBD, EOE, and Celiac)
Crohn’s Disease
A MULTICENTER, RANDOMIZED, DOUBLE‐BLIND, PARALLEL‐GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCETHERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (Arena/Pfizer)
Status: Pending sponsor to open for part 2 enrollment
Key Inclusions:
Additional information at bottom of page
Study contact:
Contact: Zvjezdana (Stella) Chroneos
717-531-8259
Study Director: Kofi Clarke, MD: Department of Medicine, Division of Gastroenterology and Hepatology
CELIAC DISEASE
A PHASE 1B OPEN‐LABEL/ PHASE 2 DOUBLE‐BLIND PLACEBO‐CONTROLLED STUDY FOR PHARMACODYNAMIC ACTIVITY, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF KAN‐101 IN PATIENTS WITH CELIAC DISEASE (Pfizer/Anokion)
Status: Recruiting
Key Inclusions:
Additional information at bottom of page
Study contact:
Contact: Zvjezdana (Stella) Chroneos
717-531-8259
Study Director: Kofi Clarke, MD: Department of Medicine, Division of Gastroenterology and Hepatology
EOSINOPHILIC ESOPHAGITIS
A PHASE 2 RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB (CDX‐0159) IN ADULTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS (The “EVOLVE” Study)(Celldex)
Status: Recruiting
Key Inclusions:
Additional information at bottom of page
Study contact:
Contact: Zvjezdana (Stella) Chroneos
717-531-8259
Study Director: Kofi Clarke, MD: Department of Medicine, Division of Gastroenterology and Hepatology
ULCERATIVE COLITIS
A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABX464 ONCE DAILY FOR INDUCTION TREATMENT IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. (Abivax)
Status: Active for enrollment
Key Inclusions:
Additional information at bottom of page
Study contact:
Contact: Zvjezdana (Stella) Chroneos
717-531-8259
Study Director: Kofi Clarke, MD: Department of Medicine, Division of Gastroenterology and Hepatology
A MULTICENTER, RANDOMIZED, DOUBLE‐BLIND, 2‐PART PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GS‐1427 IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC).
(GILEAD)
Status: Active
Key Inclusions:
Additional information at bottom of page
Study contact:
Contact: Zvjezdana (Stella) Chroneos
717-531-8259
Study Director: Kofi Clarke, MD: Department of Medicine, Division of Gastroenterology and Hepatology
